Table Graph
   

convalescent plasma treatment - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.86 [0.61, 1.22]< 10%7 studies (7/-)79.4 %lownot evaluable highcrucial-
deaths 0.91 [0.71, 1.15]< 112%11 studies (11/-)78.8 %lowlow highcrucial-
deaths (time to event analysis only) 1.37 [0.45, 4.21]< 146%2 studies (2/-)29.2 %lownot evaluable highcrucial-
clinical deterioration 0.63 [0.29, 1.40]< 10%1 study (1/-)87.0 %NAnot evaluable important-
clinical improvement 1.16 [0.87, 1.56]> 154%6 studies (6/-)84.7 %some concernserious moderateimportant-
clinical improvement (14-day) 2.27 [0.90, 5.72]> 10%1 study (1/-)95.9 %NAnot evaluable important-
clinical improvement (28-day) 1.41 [0.82, 2.45]> 165%4 studies (4/-)89.1 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.98 [0.27, 3.58]> 10%1 study (1/-)48.8 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.12 [0.92, 1.36]> 10%3 studies (3/-)86.3 %lownot evaluable highimportant-
mechanical ventilation 0.92 [0.52, 1.62]< 10%3 studies (3/-)61.3 %lownot evaluable highimportant-
mechanical ventilation (time to event analysis only) 0.66 [0.25, 1.72]< 10%1 study (1/-)80.2 %NAnot evaluable important-
viral clearance 1.12 [0.16, 7.84]> 10%1 study (1/-)54.5 %NAnot evaluable important-
viral clearance by day 14 1.51 [0.33, 6.94]> 10%1 study (1/-)70.1 %NAnot evaluable important-
ICU admission 0.82 [0.35, 1.91]< 10%1 study (1/-)67.7 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.21 [0.80, 1.83]< 163%4 studies (4/-)18.7 %lownot evaluable highimportant-
adverse events 1.08 [0.85, 1.38]< 10%1 study (1/-)26.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons